Literature DB >> 30150422

Evaluation of Different Formulations and Routes for the Delivery of the Ionizing Radiation Mitigator GS-Nitroxide (JP4-039).

Michael W Epperly1, Peter Wipf2,3, Renee Fisher1, Darcy Franicola1, Jan Beumer3, Song Li3, Rhonda M Brand4, Louis D Falo4, Geza Erdos4, Joel S Greenberger5.   

Abstract

BACKGROUND/AIM: The mitochondrial targeted GS-nitroxide, JP4-039, is an effective total body irradiation (TBI) mitigator when delivered intravenously (IV) up to 72 h after exposure. Effective systemic and localized administration to oral cavity/oropharynx and esophagus has been demonstrated. The objective of the study was to establish alternatives to IV administration suitable for JP4-039 delivery to mass casualties.
MATERIALS AND METHODS: JP4-039 was administered to C57BL/6 mice by topically applied carboxy-methyl-cellulose microneedle arrays (MNAs) or by intramuscular (IM) injection. Three different formulations that have passed Food and Drug Administration review, namely Captisol, 2-hydroxypropyl-β-cyclodextrin (cyclodextrin), and Miglyol-812-N, were used for drug delivery. Intraoral (IO) administration with each formulation was also evaluated.
RESULTS: All tested formulations and MNAs successfully delivered JP4-039. However, IM delivery of the Miglyol-812-N displayed very efficient and highly reproducible radiation mitigation.
CONCLUSION: Effective IM delivery of JP4-039 in animal models after TBI or partial-body irradiation suggested the use of the Miglyol-812-N formulation in both medical indications and radiation countermeasures. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Ionizing irradiation; JP4-039; radiation mitigation

Mesh:

Substances:

Year:  2018        PMID: 30150422      PMCID: PMC6199586          DOI: 10.21873/invivo.11341

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  37 in total

1.  Improvement of aripiprazole solubility by complexation with (2-hydroxy)propyl-β-cyclodextrin using spray drying technique.

Authors:  Tijana Mihajlovic; Kyriakos Kachrimanis; Adrijana Graovac; Zorica Djuric; Svetlana Ibric
Journal:  AAPS PharmSciTech       Date:  2012-04-26       Impact factor: 3.246

2.  Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators.

Authors:  Jean-Claude M Rwigema; Barbara Beck; Wei Wang; Alexander Doemling; Michael W Epperly; Donna Shields; Julie P Goff; Darcy Franicola; Tracy Dixon; Marie-Céline Frantz; Peter Wipf; Yulia Tyurina; Valerian E Kagan; Hong Wang; Joel S Greenberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-13       Impact factor: 7.038

3.  Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.

Authors:  Elizabeth Berry-Kravis; Jamie Chin; Anne Hoffmann; Amy Winston; Robin Stoner; Lisa LaGorio; Katherine Friedmann; Mariana Hernandez; Daniel S Ory; Forbes D Porter; Joan A O'Keefe
Journal:  Pediatr Neurol       Date:  2018-01-08       Impact factor: 3.372

4.  Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways.

Authors:  Justin Steinman; Michael Epperly; Wen Hou; John Willis; Hong Wang; Renee Fisher; Bing Liu; Ivet Bahar; Travis McCaw; Valerian Kagan; Hulya Bayir; Jian Yu; Peter Wipf; Song Li; M Saiful Huq; Joel S Greenberger
Journal:  Radiat Res       Date:  2017-11-15       Impact factor: 2.841

5.  The mitochondria-targeted nitroxide JP4-039 augments potentially lethal irradiation damage repair.

Authors:  Malolan S Rajagopalan; Kanika Gupta; Michael W Epperly; Darcy Franicola; Xichen Zhang; Hong Wang; Hong Zhao; Vladimir A Tyurin; Joshua G Pierce; Valerian E Kagan; Peter Wipf; Anthony J Kanai; Joel S Greenberger
Journal:  In Vivo       Date:  2009 Sep-Oct       Impact factor: 2.155

6.  Corneal Collagen Cross-Linking for the Management of Mycotic Keratitis.

Authors:  Elif Erdem; Ibrahim Inan Harbiyeli; Hazal Boral; Macit Ilkit; Meltem Yagmur; Reha Ersoz
Journal:  Mycopathologia       Date:  2018-02-16       Impact factor: 2.574

7.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

8.  Strategies for discovery of small molecule radiation protectors and radiation mitigators.

Authors:  Joel S Greenberger; David Clump; Valerian Kagan; Hülya Bayir; John S Lazo; Peter Wipf; Song Li; Xiang Gao; Michael W Epperly
Journal:  Front Oncol       Date:  2012-01-13       Impact factor: 6.244

9.  A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.

Authors:  Samantha H Dallefeld; Andrew M Atz; Ram Yogev; Janice E Sullivan; Amira Al-Uzri; Susan R Mendley; Matthew Laughon; Christoph P Hornik; Chiara Melloni; Barrie Harper; Andrew Lewandowski; Jeff Mitchell; Huali Wu; Thomas P Green; Michael Cohen-Wolkowiez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-12       Impact factor: 2.410

10.  Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials.

Authors:  Shuxin Luan; Hongquan Wan; Lei Zhang; Hua Zhao
Journal:  Neuropsychiatr Dis Treat       Date:  2018-02-08       Impact factor: 2.570

View more
  5 in total

1.  Anti-Ferroptosis Drug Enhances Total-Body Irradiation Mitigation by Drugs that Block Apoptosis and Necroptosis.

Authors:  Stephanie Thermozier; Wen Hou; Xichen Zhang; Donna Shields; Renee Fisher; Hulya Bayir; Valerian Kagan; Jian Yu; Bing Liu; Ivet Bahar; Michael W Epperly; Peter Wipf; Hong Wang; M Saiful Huq; Joel S Greenberger
Journal:  Radiat Res       Date:  2020-03-05       Impact factor: 2.841

2.  Radioresistance of Serpinb3a-/- Mice and Derived Hematopoietic and Marrow Stromal Cell Lines.

Authors:  Stephanie Thermozier; Xichen Zhang; Wen Hou; Renee Fisher; Michael W Epperly; Bing Liu; Ivet Bahar; Hong Wang; Joel S Greenberger
Journal:  Radiat Res       Date:  2019-07-11       Impact factor: 2.841

3.  Fanconi Anemia Mouse Genotype-specific Mitigation of Total Body Irradiation by GS-Nitroxide JP4-039.

Authors:  Michael W Epperly; Renee Fisher; Xichen Zhang; Wen Hou; Donna Shields; Peter Wipf; Hong Wang; Stephanie Thermozier; Joel S Greenberger
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

4.  Second-generation Probiotics Producing IL-22 Increase Survival of Mice After Total Body Irradiation.

Authors:  Xichen Zhang; Renee Fisher; Wen Hou; Donna Shields; Michael W Epperly; Hong Wang; Liang Wei; Brian J Leibowitz; Jian Yu; Laura M Alexander; Jan-Peter VAN Pijkeren; Simon Watkins; Peter Wipf; Joel S Greenberger
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

5.  Amelioration of Mucositis in Proton Therapy of Fanconi Anemia Fanca-/- Mice by JP4-039.

Authors:  Thomas J Quinn; Xuanfeng Ding; Xiaoqiang Li; George D Wilson; Katie Buelow; Aranee Sivananthan; Stephanie Thermozier; Andrew Henderson; Michael W Epperly; Darcy Franicola; Peter Wipf; Joel S Greenberger; Craig W Stevens; Peyman Kabolizadeh
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.